EP0808906B1 - Use of an osmolyte for reducing or abolishing non-covalent interactions of biological molecules to inert surfaces - Google Patents

Use of an osmolyte for reducing or abolishing non-covalent interactions of biological molecules to inert surfaces Download PDF

Info

Publication number
EP0808906B1
EP0808906B1 EP96108278A EP96108278A EP0808906B1 EP 0808906 B1 EP0808906 B1 EP 0808906B1 EP 96108278 A EP96108278 A EP 96108278A EP 96108278 A EP96108278 A EP 96108278A EP 0808906 B1 EP0808906 B1 EP 0808906B1
Authority
EP
European Patent Office
Prior art keywords
osmolyte
betaine
pcr
silicon
zwitterionic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96108278A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0808906A1 (en
Inventor
Elmar Maier
Igor Ivanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qiagen GmbH
Original Assignee
Qiagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qiagen GmbH filed Critical Qiagen GmbH
Priority to AT96108278T priority Critical patent/ATE196510T1/de
Priority to EP96108278A priority patent/EP0808906B1/en
Priority to DE69610410T priority patent/DE69610410T2/de
Priority to JP13337097A priority patent/JP4113603B2/ja
Publication of EP0808906A1 publication Critical patent/EP0808906A1/en
Application granted granted Critical
Publication of EP0808906B1 publication Critical patent/EP0808906B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase

Definitions

  • the present invention relates to the use of a zwitterionic osmolyte of formula as in claim 1 for reducing or abolishing non-covalent interactions of biological molecules to inert surfaces. Furthermore, the present invention relates to kits that may be employed for uses in accordance with the present invention.
  • bovine serum albumin (BSA) is employed as a saturation agent prior to testing for the relevant antibodies or serum.
  • BSA bovine serum albumin
  • Other methods for reducing non-specific binding and/or edge effects on ELISA microtitre plates comprise the addition of sugar and/or alcohol, like glycerol to reaction mixtures, as disclosed in EP-A-0153875.
  • PCR technology A technology that has in the most recent past revolutionized molecular biology is the PCR technology.
  • major efforts have been and are presently undertaken to further improve facettes of this technology.
  • One of these efforts is directed to the creation of microreaction volumes of PCR chips, i.e. microfabricated silicon chips bonded to a piece of flat glass to form a PCR reaction chamber; see, e.g., Shoffner et al., "Chip PCR. I. Surface passivation of microfabricated silicon-glass chips for PCR", Nucl. Acids Res. 24 (1996), 375-379.
  • the technical problem underlying the present invention was to overcome the prior art problems detailed hereinabove and develop a system that reduces or eliminates undesired interactions of biological molecules with inert surfaces.
  • the present invention relates to the use of a zwitterionic osmolyte with formula as in claim 1 for reducing or abolishing non-covalent interactions of biological molecules to inert surfaces.
  • a zwitterionic osmolyte having the structural formula wherein R 1 , R 2 and R 3 are H, CH 3 , C 2 H 5 or any other alkyl, and R is any amino acid residue, in a suitable concentration to a solution comprising a biological molecule will reduce, if not abolish the non-covalent interaction of said molecule with said surface.
  • Osmolytes are found in a wide variety of water-stressed prokaryotic and eukaryotic organisms.
  • the three types of osmolyte systems found in all such organisms except for the halobacteria are polyhydric alcohols (such as glycerol and saccharose), free amino acids and their derivatives (such as taurine and ⁇ -alanine), and methylamines (e.g.
  • TMAO trimethylamine-N-oxide
  • betaine betaine
  • sarcosine trimethylamines and urea
  • One of the major advantages of the present invention is that the simple addition of a zwitterionic osmolyte having the formula as in claim 1 to such a solution conveniently reduces or abolishes the interaction of said molecules with a wide variety of inert surfaces. The special design or selection of an adequate surface for a specific experimental set-up or purpose is therefore no longer necessary.
  • a further advantage of the present invention is that it allows for the simple design of a variety of previously crucial experiments and therefore saves time and costs for the interested investigator.
  • biological molecule refers to organic molecules which are part of an organism or a living cell or derivatives of such molecules. These molecules may be of natural, synthetic or semisynthetic origin.
  • inert has the meaning of “having little or no ability to chemically react”. It therefore bears the same meaning as inertness in connection with nitrogens which occurs uncombined in the atmosphere.
  • said zwitterionic osmolyte is an amino acid or its methylation product.
  • said zwitterionic osmolyte is betaine and preferably glycine-betaine.
  • said osmolyte is present at a final concentration of 1 to 2.5 M.
  • the advantageous properties of said osmolyte also emerge, if it is included in the reaction mixture at a lower concentration than 1 M. However, particularly advantageous results are obtained, if the osmolyte is present in a final concentration of 1 to 2.5 M.
  • said biological molecule is a macromolecule.
  • micromolecule in connection with the term “biological molecule” is perfectly clear to the person skilled in the art and need not be described here any further.
  • said macromolecule is a carbohydrate, a polynucleic acid or a polypeptide, or combinations or modifications thereof. Said combinations or modifications need not necessarily have a biological function. In the alternative, their biological function may not be known in the art (yet); see, for example, the discussion about peptide nucleic acids (Nielsen et al., Science 254 (1991), 1497-1500) .Yet, said modified biological macromolecules may have essentially the same physicochemical properties as the biological macromolecules they are derived from and may find the same or similar applications e.g. in molecular biology.
  • said biological molecule is a peptide or an oligonucleotide or combinations or modifications thereof.
  • said polynucleic acid or oligonucleotide is DNA.
  • DNA as used herein includes any type of DNA, in particular cDNA and genomic DNA.
  • RNA is intended to mean any type of RNA and in particular mRNA.
  • said inert surface is a silicon surface, a silicon wafer, a glass surface or combinations or chemical modifications thereof.
  • said substance is a manufactured silicon.
  • Said silicon may be obtained e.g., by standard manufacturing or processing techniques such as photolithography.
  • the present invention additionally relates to a kit comprising at least
  • the various components of the kit of the present invention are preferably formulated in standard reaction vials and independently of one another.
  • concentrations used in the stock solutions comprised in the kit of the invention are suitable to allow an appropriate dilution of the osmolyte to be useful in the teachings of the present invention.
  • the osmolyte is preferably contained therein in its final concentration. The ranges and limits of said final concentrations have been provided herein before in the specification.
  • Figure 1 PCR in the presence of silicon particles and zwitterionic osmolytes
  • PCRs were carried out on a 1.2 kb fragment of human genomic DNA in the presence of silicon particles (approx: 0.5 mm x 0.5 mm x 0.3 mm) and 1 M betaine.
  • Lane 1 ⁇ -BstEII marker
  • lanes 2-5 PCR (50 ⁇ l) carried out in buffer with water and different amounts of silicon particles: lane 2: 10 particles; lane 3: 50 particles; lane 4: 75 particles; lane 5: no particles as a control
  • lanes 6-9 PCRs (50 ⁇ l) carried out in buffer with 1 M betaine and different amounts of silicon particles: lane 6: 10 particles; lane 7: 50 particles; lane 8: 75 particles; lane 9: no particles as a control.
  • Figure 2 PCR in the presence of silicon powder and zwitterionic osmolytes
  • PCRs were carried out on a 1.5 kb fragment of human genomic DNA in the presence of silicon powder and molar concentrations of betaine. Note that the PCRs in molar concentrations of betaine allow efficient and specific PCR amplification and reduce the inhibiting effect of silicon surfaces.
  • Lane 1 ⁇ -BstEII marker
  • lane 2 PCR carried out in a standard PCR buffer without any silicon powder
  • lanes 3-6 PCR reaction carried out with 4.6 mg of silicon powder in 100 ⁇ l PCR volume
  • lane 3 water based buffer
  • lane 4 0.5 M betaine
  • lane 5 1 M betaine
  • lane 6 2 M betaine.
  • Example 1 PCR in the presence of silicon particles and zwitterionic osmolytes
  • each primer M13-40 (24-mer): 5'-CGCCAGGGTTTTCCCAGTCACGAC-3'; M13-Rev (24-mer): 5'-TTTCACACAGGAAACAGCTATGAC-3'), 100 ⁇ M of each dNTP, 1.5 mM MgCl 2 and 2.5 Units of Taq DNA polymerase in a total volume of 50 ⁇ l.
  • Reaction mixtures containing betaine were prepared by adding the required mixture of water and a 5 M stock solution of betaine to the final reaction volume of 50 ⁇ l. The mixtures were cycled 30 times at 94°C for 20 sec, 55°C for 30 sec and at 73°C for 2 min 30 sec.
  • Example 2 PCR in the presence of silicon powder and zwitterionic osmolytes
  • PCRs were carried out in 1x buffer (10 mM Tris-HCI, pH 8.8 and 50 mM KCI) in water only (Fig. 2, lane 2) and 4.6 mg of silicon powder (Fig. 2, lanes 3-6) in water (Fig. 2, lanes 3), 0.5 M betaine (Fig. 2, lane 4), 1 M betaine (Fig. 2, lane 5), 2 M betaine (Fig.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
EP96108278A 1996-05-23 1996-05-23 Use of an osmolyte for reducing or abolishing non-covalent interactions of biological molecules to inert surfaces Expired - Lifetime EP0808906B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT96108278T ATE196510T1 (de) 1996-05-23 1996-05-23 Verwendung eines osmolyten zur verringerung oder aufhebung von nichtkovalenten bindungen biologischer moleküle an inerten oberflächen
EP96108278A EP0808906B1 (en) 1996-05-23 1996-05-23 Use of an osmolyte for reducing or abolishing non-covalent interactions of biological molecules to inert surfaces
DE69610410T DE69610410T2 (de) 1996-05-23 1996-05-23 Verwendung eines Osmolyten zur Verringerung oder Aufhebung von nichtkovalenten Bindungen biologischer Moleküle an inerten Oberflächen
JP13337097A JP4113603B2 (ja) 1996-05-23 1997-05-23 浸透物質の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96108278A EP0808906B1 (en) 1996-05-23 1996-05-23 Use of an osmolyte for reducing or abolishing non-covalent interactions of biological molecules to inert surfaces

Publications (2)

Publication Number Publication Date
EP0808906A1 EP0808906A1 (en) 1997-11-26
EP0808906B1 true EP0808906B1 (en) 2000-09-20

Family

ID=8222814

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96108278A Expired - Lifetime EP0808906B1 (en) 1996-05-23 1996-05-23 Use of an osmolyte for reducing or abolishing non-covalent interactions of biological molecules to inert surfaces

Country Status (4)

Country Link
EP (1) EP0808906B1 (ja)
JP (1) JP4113603B2 (ja)
AT (1) ATE196510T1 (ja)
DE (1) DE69610410T2 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7993853B2 (en) 2005-05-06 2011-08-09 Gen-Probe Incorporated Methods of nucleic acid target capture

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4104285B2 (ja) * 1997-08-14 2008-06-18 タカラバイオ株式会社 Ｄｎａ増幅方法及びそのキット
JP7096482B2 (ja) * 2017-12-05 2022-07-06 藤倉化成株式会社 感作された不溶性担体粒子を含有する免疫測定試薬の劣化防止手段

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153875A3 (en) * 1984-03-01 1987-06-24 The State Of Victoria Enzyme-linked immunosorbent assay method and test kit
DE3717402A1 (de) * 1987-05-23 1988-12-08 Behringwerke Ag Verfahren zur bestimmung von proteinen und mittel dazu
US5047326A (en) * 1988-10-07 1991-09-10 Eastman Kodak Company Immunmological reagent composition and its use in the determination of chlamydial or gonococcal antigens
DE69303898T3 (de) * 1992-05-01 2007-01-18 Trustees Of The University Of Pennsylvania Fluessigkeitsbehandlung in mikrofabrizierten analytischen vorrichtungen
DE69531487T2 (de) * 1994-01-31 2004-06-17 The Regents Of The University Of California, Oakland Methode zur eliminierung von sequenzierartefakten
US5512462A (en) * 1994-02-25 1996-04-30 Hoffmann-La Roche Inc. Methods and reagents for the polymerase chain reaction amplification of long DNA sequences
DE4411588C1 (de) * 1994-03-30 1995-09-28 Deutsches Rheuma Forschungszen Puffer für DNA- und RNA-Polymerase-Reaktionen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochemistry, 32(1), 1993, 137-144 *
J. Immunological Methods, 90, 1986, 105-110 *
Nucleic Acids Research, 24(2), 1996, 375-379 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7993853B2 (en) 2005-05-06 2011-08-09 Gen-Probe Incorporated Methods of nucleic acid target capture

Also Published As

Publication number Publication date
ATE196510T1 (de) 2000-10-15
DE69610410T2 (de) 2001-05-10
EP0808906A1 (en) 1997-11-26
DE69610410D1 (de) 2000-10-26
JPH1066596A (ja) 1998-03-10
JP4113603B2 (ja) 2008-07-09

Similar Documents

Publication Publication Date Title
US6150094A (en) Use of an osmolyte for reducing or abolishing no-covalent interactions of biological molecules to inert surfaces
Erdmann et al. The involvement of 5S RNA in the binding of tRNA to ribosomes
US8192958B2 (en) Nucleic acid isolation using polidocanol and derivatives
WILK et al. The core proteins of 35 s hnRNP complexes: characterization of nine different species
Wickner et al. DnaJ, DnaK, and GrpE heat shock proteins are required in oriP1 DNA replication solely at the RepA monomerization step.
KR102088381B1 (ko) 압타머-기반 다중 검정법
WO2006103094A3 (de) Verfahren zur behandlung einer biomoleküle enthaltenden probe
EP0503000A1 (en) Promotion of high specificity molecular assembly
EP3177931B1 (en) Method of determination of the ability of substances to bind to analyte active sites
EP1932913B1 (en) Nucleic acid isolation using polidocanol and derivatives
EP0808906B1 (en) Use of an osmolyte for reducing or abolishing non-covalent interactions of biological molecules to inert surfaces
EP2951300B1 (en) Robust, easy to use immobilized enzyme reactors
Wang et al. Determinants for Escherichia coli RNA polymerase assembly within the β subunit
DiPaolo et al. Monitoring impurities in biopharmaceuticals produced by recombinant technology
US20090035803A1 (en) Method for stabilization of peptides in a biological sample
Weeks et al. Role of ribosomal subunits in eukaryotic protein chain initiation
Dröge et al. Inhibition of DNA synthesis by aphidicolin induces supercoiling in simian virus 40 replicative intermediates.
Heinrikson Selective S-methylation of cysteine in proteins and peptides
JP2000146911A (ja) 核酸を分離する方法
US20080124781A1 (en) Enzymes with modified amino acids
WO2007051605A2 (de) Verfahren zur bestimmung der spaltbarkeit von substraten
EP0751226A3 (en) Process for amplifying nucleic acid sequences
JP3531372B2 (ja) 新規なポリペプチド及びそれを用いる生体成分測定方法
Ono et al. Inhibitory effects of various 5-halogenated derivatives of 1-. beta.-D-arabinofuranosyluracil 5'-triphosphate on DNA polymerases from murine cells and oncornavirus: substituent effects on inhibitory action
JP3767597B2 (ja) 新規なポリペプチド及びそれを用いる生体成分測定方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

17Q First examination report despatched

Effective date: 19980812

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: QIAGEN GMBH

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RTI1 Title (correction)

Free format text: USE OF AN OSMOLYTE FOR REDUCING OR ABOLISHING NON-COVALENT INTERACTIONS OF BIOLOGICAL MOLECULES TO INERT SURFACES

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000920

REF Corresponds to:

Ref document number: 196510

Country of ref document: AT

Date of ref document: 20001015

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69610410

Country of ref document: DE

Date of ref document: 20001026

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

ITF It: translation for a ep patent filed

Owner name: BIANCHETTI - BRACCO - MINOJA S.R.L.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20001220

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SCHMAUDER & PARTNER AG PATENTANWALTSBUERO

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010523

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: SCHMAUDER & PARTNER AG PATENT- UND MARKENANWAELTE VSP;ZWAENGIWEG 7;8038 ZUERICH (CH)

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20150520

Year of fee payment: 20

Ref country code: DE

Payment date: 20150521

Year of fee payment: 20

Ref country code: GB

Payment date: 20150521

Year of fee payment: 20

Ref country code: CH

Payment date: 20150521

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20150520

Year of fee payment: 20

Ref country code: AT

Payment date: 20150521

Year of fee payment: 20

Ref country code: BE

Payment date: 20150520

Year of fee payment: 20

Ref country code: FR

Payment date: 20150521

Year of fee payment: 20

Ref country code: IT

Payment date: 20150515

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69610410

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20160522

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20160522

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 196510

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160522